The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: boost, brachytherapy, effectiveness, risk, safety, Treatment, type | Leave a comment »
There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, mCRPC, PARP, Phase III, trial | Leave a comment »
Near the end of last month we had told you that data from the LATITUDE trial and from Arm G of the STAMPEDE trial would be presented at the ASCO annual meeting in Chicago this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, outcome, trial, Zytiga | Leave a comment »
Scott Monserud is the sports editor for The Denver Post in Denver, CO. In the first of a series of articles entitled “Help, and Hope: A Cancer Journal” he writes about his own personal experience. Click here to get his tale.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | 1 Comment »
The American Society for Clinical Oncology (ASCO) just released the abstracts for the hundreds of presentations and posters that will be given at the upcoming annual meeting of ASCO in June in Chicago. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abstract, annual, ASCO, meeting | 11 Comments »
An announcement from Johnson & Johnson yesterday said that the company is projecting filings with regulatory authorities for approval of two new drugs for the treatment of advanced prostate cancer between 2017 and 2021. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: apalutamide, ARN-509, niraparib | 2 Comments »
